New research shows that loose or sagging skin on the face and neck is most often noted after medication-driven weight loss, with facial changes typically observed 3-6 months following treatment (in 45% of respondents), and sometimes as early as 1-2 months (28%)1
In addition, more than 60% of those patients experiencing medication-driven weight loss show a strong interest in a dual-expertise service that integrates both medical and aesthetic professionals to support them during their weight loss journey1
At IMCAS, Galderma will further educate healthcare professionals on this topic by hosting a masterclass with international aesthetics experts who will delve into how to manage facial changes in patients experiencing medication-driven weight loss, in clinical practice
Additionally, the first international consensus-based guidelines by global experts for understanding and managing the unique aesthetic needs of this patient population, supported by Galderma, will be presented as part of a session dedicated to rapid facial volume loss2
ZUG, Switzerland--(BUSINESS WIRE)--Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight loss on the skin and the importance of factoring in aesthetic treatment goals during the patient’s journey, as well as the first international consensus-based guidelines from global experts on how to treat this patient population.
Today, at the International Master Course on Aging Science (IMCAS) 2025 annual congress, Galderma will also host a first-of-its-kind masterclass on this topic with international aesthetics experts. Titled “Managing Facial Changes in Patients with Medication-Driven Weight-Loss”, the session will be the opportunity to discuss strategies for managing facial changes in this patient population in clinical practice.
While the rates and stages of adoption differ worldwide, the use of prescription weight loss medications is set to increase globally, with $100 billion sales globally forecasted by 2030, which will have a considerable impact on aesthetics for both patients and healthcare professionals3. With 62% of patients using glucagon-like peptide-1 (GLP-1) getting aesthetic treatment following a healthcare professional recommendation1, there is a clear need for guidance on how to treat this new patient population.
First international consensus-based guidelines
Recognizing the significance and broad impact of prescription weight loss medications, Galderma commissioned the Delphi study to address the need for high-quality research in this area and help establish clinical guidelines for identifying and managing the unique needs of this patient population. This international, multidisciplinary study — incorporating patient interviews, market research, literature reviews, and insights from global experts with extensive experience in treating medication-driven weight loss patients — culminated in a global consensus on key criteria, expert perspectives, and treatment prioritization, all supported by real-world case studies2. These novel consensus guidelines, submitted for publication as the first international consensus-based guidelines from global experts on how to treat this patient population, will be presented by Dr. Andreas Nikolis, during a focus session on “Rapid facial volume loss: causes and consequences” on January 31st, 2025 in the Grand Amphi.
Additionally, Galderma has surveyed more than 1,000 male and female respondents using weight loss medications, aged between 25-65 across the United States, Brazil, Europe and the Middle East1. The focus is understanding the anatomical and aesthetic impact of medication-driven weight loss on the skin, to help equip healthcare professionals to guide patients effectively along their weight loss and aesthetics journey, based on their unique needs.
|
“With 23% of patients who are already or plan to undergo specific aesthetic treatments, we are now witnessing the emergence of a distinct patient population — those who have undergone significant weight loss and are now seeking complementary aesthetic care. With unique needs, these patients require a thoughtful, integrated approach from healthcare providers. Galderma’s cutting-edge research plays a pivotal role in equipping healthcare providers with the knowledge they need to stay at the forefront of this shift. By addressing these patients' specific concerns from the outset, we can provide a more holistic, tailored approach that enhances both physical transformation and overall well-being.”
DR. ANDREAS NIKOLIS, M.D., PH.D., FRCSC, BOARD-CERTIFIED PLASTIC SURGEON MONTREAL, CANADA
|
|
